DEFM14A filed Nov 9, 2026 at 16:45 ET
JATT II Acquisition Corp. is holding a shareholder vote on December 2, 2026 to approve its business combination with Talawar Tx Inc., a biopharmaceutical company. Under the deal, Talawar stockholders will receive approximately 12.5 million shares of the combined company (valued at $120 million at $10/share), JATT public shareholders will receive one share per JATT share, and a $225 million PIPE at $10/share will close concurrently. The JATT board unanimously recommends approval (with Dr. Sidhu recused due to conflicts as Talawar's majority stockholder and Khanda's CEO), and Houlihan Capital opined the consideration is fair to JATT's unaffiliated shareholders.